Google+ Facebook Twitter Twitter

Response to COVID-19 reduced in patients with blood cancers

Patients with blood cancers vary in their immune response to COVID-19 and can struggle to clear infection for many weeks, according to new research published in Cancer Cell.

By contrast, most patients with solid tumours, even those with advanced cancer, can mount an effective and lasting immune defence.

The team from King’s College London and the Francis Crick Institute analysed the blood of 76 cancer patients – 41 who had COVID-19 and 35 who had not been exposed to the virus. A total of 23 of the people with cancer had solid tumours, and 18 had blood cancers.

When they compared samples with the immune signatures from COVID-19 patients without cancer, they saw that patients with solid tumours had a similar immune response to those without cancer, regardless of cancer stage or if they were undergoing treatment. However, the immune response of patients with blood cancers varied considerably.

Image Credit | iStock

Related Articles


A new COVID-19 test that reduces testing time from 30 minutes to less than five and delivers accurate results has been developed by scientists at the University of Birmingham.

The great big biomedical quiz (Kip Heath special)

For the first instalment of our biomedical science quiz in 2021, we hand the reigns over to healthcare scientist and contestant on a number of TV quizzes, Kip Heath. (Click on the link at the bottom of the quiz to see the answers.)

Creating a COVID laboratory

Microbiology Service Lead Susan Lovegrove outlines the process of creating a new PCR laboratory at Black Country Pathology Services.

Strains and mutations: The emerging threat

Is the evolution of SARS-CoV-2 and the emerging variants going to effect attempts to inoculate against the virus? We look at the issues.